Axovant Announces Negative Topline Results of Intepirdine Phase 3 MINDSET Trial in Alzheimer's Disease
Go back to Axovant Announces Negative Topline Results of Intepirdine Phase 3 MINDSET Trial in Alzheimer's Disease| Axion Spatial Imaging Inc (NASDAQ: AXON) | Delayed: 505.43 -10.24 (1.99%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $515.67 | 52 Week High | $21.30 | |||
| Open | $506.03 | 52 Week Low | $8.86 | |||
| Day High | $514.62 | P/E | N/A | |||
| Day Low | $501.37 | EPS | $0.00 | |||
| Volume | 735,530 | |||||
